A cytosine analog that confers enhanced potency to antisense oligonucleotides

Autor Flanagan, W. Michael, Wolf, John J., Olson, Peter, Grant, Debbie, Lin, Kuei-Ying, Wagner, Richard W., Matteucci, Mark D.
Vydáno 1999

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

Autor Meng, Fanying, Bhupathi, Deepthi, Sun, Jessica D, Liu, Qian, Ahluwalia, Dharmendra, Wang, Yan, Matteucci, Mark D, Hart, Charles P
Vydáno v BMC Cancer (2015)

Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models

Autor Sun, Jessica D., Liu, Qian, Ahluwalia, Dharmendra, Ferraro, Damien J., Wang, Yan, Jung, Don, Matteucci, Mark D., Hart, Charles P.
Vydáno v Cancer Biol Ther (2016)

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models

Autor Sun, Jessica D, Ahluwalia, Dharmendra, Liu, Qian, Li, Wenwu, Wang, Yan, Meng, Fanying, Bhupathi, Deepthi, Matteucci, Mark D, Hart, Charles P
Vydáno v Am J Cancer Res (2015)

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

Autor Liu, Qian, Sun, Jessica D., Wang, Jingli, Ahluwalia, Dharmendra, Baker, Amanda F., Cranmer, Lee D., Ferraro, Damien, Wang, Yan, Duan, Jian-Xin, Ammons, W. Steve, Curd, John G., Matteucci, Mark D., Hart, Charles P.
Vydáno 2012